Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
Stabilization priorities
Airway protection triggers
GCS < 8
Refractory vomiting with aspiration risk
Severe agitation preventing oxygenation or monitoring
Breathing targets
SpO2 94% to 98%
If chronic hypercapnia risk, SpO2 88% to 92%
Circulation targets
MAP at least 65 mmHg
SBP at least 90 mmHg
Immediate reversible causes of delirium
Hypoglycemia
Hypoxia
Hyperthermia
Sepsis
High risk withdrawal recognition
Delirium tremens features
Delirium
Autonomic hyperactivity
Severe agitation
Hallucinations
Onset typically 48 to 96 hours after last drink
Withdrawal seizure risk window
6 to 48 hours after last drink
Wernicke encephalopathy risk
Confusion
Ataxia
Ophthalmoplegia or nystagmus
Monitoring and environment
Cardiorespiratory monitoring
Continuous ECG
Continuous pulse oximetry
Frequent noninvasive BP
Safety measures
Low stimulation room
1 to 1 observation for severe agitation
Fall precautions
Early escalation triggers
ICU indications
Delirium tremens
Recurrent seizures
Benzodiazepine resistant withdrawal
Need for continuous sedative infusion
Severe comorbidity
Airway team activation
Escalating sedation requirement with loss of airway reflexes
Persistent hypoventilation
Parallel actions bundle
Thiamine before glucose
Thiamine IV before any dextrose containing fluids when malnutrition risk
Glucose treatment not delayed if severe hypoglycemia
Electrolyte correction priorities
Potassium
Magnesium
Phosphate
Co-ingestant and alternate diagnosis screen
Head trauma
CNS infection
Hepatic encephalopathy
Toxic ingestion
Risk stratification and severity targets
Severity framework
Mild withdrawal
Tremor
Anxiety
Insomnia
Moderate withdrawal
Marked autonomic symptoms
Nausea or vomiting
Perceptual disturbances without delirium
Severe withdrawal
Seizure
Delirium
Severe autonomic instability
Treatment strategy selection
Symptom triggered benzodiazepines
Appropriate for mild to moderate withdrawal
Requires reliable scoring and monitoring
Fixed dose benzodiazepines
Appropriate when scoring unreliable
Cognitive impairment
History of severe withdrawal
Front loading
Diazepam based when rapid control needed and hepatic function adequate
Phenobarbital based strategy
Benzodiazepine resistant withdrawal
High risk severe withdrawal at presentation
Clinical targets
Agitation control
Calm but arousable
Able to protect airway
Autonomic stabilization
HR trending down
BP trending down
Temperature trending to normal
History
Focused elements
Withdrawal timeline
Time of last alcohol
Hours since last drink
Prior peak severity timing
Typical progression features
Tremor onset time
Hallucinations onset time
Seizure onset time
Alcohol exposure
Daily quantity
Standard drinks per day
Pattern of binge use
Duration of heavy use
Months or years
Recent reduction or cessation
Abrupt stop
Forced abstinence
Prior severe withdrawal
Prior delirium tremens
Prior withdrawal seizures
Prior ICU admission for withdrawal
Co-substances
Benzodiazepines
Opioids
Stimulants
Cannabis
Comorbid illness raising risk
Liver disease
Heart failure
COPD or OSA
Infection symptoms
GI bleed symptoms
Medication history
Recent sedatives
Antipsychotics
Beta blockers
Nutrition and deficiency risk
Poor intake
Weight loss
Recurrent vomiting
Psychiatric and safety context
Baseline psychosis history
Mania history
Current suicidal thoughts
Access to alcohol after discharge
Social determinants
Reliable caregiver for outpatient plan
Stable housing
Follow up access
Classic presentation and pitfalls
Typical syndromes
Early withdrawal
Tremor
Anxiety
Diaphoresis
Alcoholic hallucinosis
Visual hallucinations
Preserved orientation
Withdrawal delirium
Disorientation
Fluctuating attention
Severe autonomic hyperactivity
Pitfalls
Delirium not always withdrawal
Infection
Head injury
Metabolic encephalopathy
Tachycardia from other causes
PE
GI bleed
Thyrotoxicosis
Physical Exam
Key findings and severity markers
Vital signs and instability
Autonomic hyperactivity
Tachycardia
Hypertension
Fever
Diaphoresis
Respiratory compromise
Bradypnea from sedatives
Hypoxia
Neurologic and mental status
Withdrawal signs
Tremor
Hyperreflexia
Mydriasis
Delirium markers
Inattention
Disorientation
Agitation
Seizure evidence
Tongue bite
Postictal confusion
Wernicke encephalopathy signs
Nystagmus
Ophthalmoplegia
Gait ataxia
Trauma and alternate cause screen
Head and neck
Scalp hematoma
Cervical tenderness
Cardiopulmonary
Arrhythmia
Pulmonary edema
Abdomen
Ascites
RUQ tenderness
Skin and infection
Cellulitis
Track marks
Hydration and nutrition
Dehydration
Dry mucous membranes
Orthostasis
Malnutrition signs
Temporal wasting
Glossitis
PITFALLS
Diagnostic traps
Persistent fever not assumed withdrawal
Pneumonia consideration
Meningitis consideration
Severe agitation masking hypoxia
Pulse oximetry artifact consideration
Sedation masking neurologic deficit
Serial neuro checks after stabilization
Differential Diagnosis
Life threats and common mimics
Delirium differential
Alcohol withdrawal delirium (ICD-10 F10.231)
Sepsis associated encephalopathy (ICD-10 R65.20)
Hypoglycemia (ICD-10 E16.2)
CNS infection (ICD-10 G00.9)
Intracranial hemorrhage (ICD-10 I62.9)
Toxic ingestion
Ethylene glycol (ICD-10 T51.2)
Methanol (ICD-10 T51.1)
Seizure differential
Withdrawal seizure (ICD-10 F10.239)
Epilepsy (ICD-10 G40.909)
Hyponatremia (ICD-10 E87.1)
Hypomagnesemia (ICD-10 E83.42)
Stimulant intoxication (ICD-10 F15.929)
Agitation and psychosis differential
Primary psychosis (ICD-10 F29)
Manic episode (ICD-10 F30.9)
Serotonin syndrome (ICD-10 T43.205A)
Neuroleptic malignant syndrome (ICD-10 G21.0)
Thyroid storm (ICD-10 E05.91)
Medical complications of alcohol use
Complication differential
Alcoholic ketoacidosis (ICD-10 E87.2)
Pancreatitis (ICD-10 K85.90)
Upper GI bleed (ICD-10 K92.2)
Hepatic encephalopathy (ICD-10 K72.90)
Arrhythmia
Atrial fibrillation (ICD-10 I48.91)
Laboratory Tests
Core labs and immediate corrections
Baseline panel
Electrolytes and renal function
Sodium
Potassium
Chloride
Bicarbonate
Creatinine
Glucose
Point of care glucose mmol/L for altered mental status
Recheck after dextrose therapy
Magnesium
Replacement threshold planning
Arrhythmia and seizure risk modifier
Phosphate
Refeeding risk marker
Respiratory muscle weakness risk
Hematology and liver
Complete blood count
Leukocytosis for infection consideration
Thrombocytopenia for liver disease and bleed risk
Liver panel
AST
ALT
ALP
Bilirubin
Albumin
Coagulation
INR
Acid base and perfusion
Venous blood gas or arterial blood gas
pH
PaCO2 mmHg
PaO2 mmHg
Lactate mmol/L
Sepsis marker
Seizure related elevation consideration
Toxicology and related
Blood ethanol
Co-intoxication indicator
Withdrawal can occur with detectable ethanol
Urine drug screen
Stimulants
Benzodiazepines
Opioids
Targeted labs by presentation
Complication workup
Beta hydroxybutyrate
Alcoholic ketoacidosis support
Lipase
Pancreatitis support
Creatine kinase
Rhabdomyolysis support
Troponin
Chest pain
Demand ischemia
Blood cultures
Fever
Hypotension
Deficiency and endocrinology adjuncts
Thiamine level not required for treatment
Treatment not delayed for labs
TSH
Thyrotoxicosis mimic
Pregnancy testing
Beta hCG in people who can become pregnant
Medication risk adjustment
Interpretation pearls and pitfalls
Common abnormalities
Hypomagnesemia common in alcohol use disorder
Hypokalemia often coexists with hypomagnesemia
Hypophosphatemia with malnutrition or refeeding
Pitfalls
Leukocytosis from stress or seizure
Elevated lactate from seizure without sepsis
Diagnostic Tests
Scoring Systems
Validated tools
CIWA-Ar
Symptom triggered benzodiazepine suitability
Not reliable in delirium or intubation
PAWSS
Predicts severe withdrawal risk
Useful for prophylaxis planning
MINDS
ICU oriented monitoring alternative
Useful when CIWA-Ar not feasible
Application rules
CIWA-Ar limitations
Requires patient report and cooperation
Overestimates in primary psychosis
Severe withdrawal clinical override
DT treated as severe regardless of score
MRI
Neuroimaging indications
Persistent focal neurologic deficit after stabilization
Suspected Wernicke encephalopathy with atypical course
Concern for encephalitis with normal CT
Practical limitations
Limited feasibility in severe agitation
Airway and monitoring constraints
CT
Head CT indications
Head trauma history
Focal neurologic deficit
New seizure without clear withdrawal context
Persistent altered mental status despite adequate withdrawal control
Chest imaging indications
Aspiration concern
Hypoxia
Fever
Abdomen CT indications
Severe abdominal pain
Suspected pancreatitis complication
Evidence note
Routine head CT not required for typical withdrawal seizure with rapid recovery
Ultrasound
Point of care uses
Cardiac ultrasound
Cardiomyopathy assessment
Volume status adjunct
Lung ultrasound
Pulmonary edema
Pneumonia support
RUQ ultrasound
Ascites assessment
Biliary pathology consideration
Procedural guidance
IV access guidance in difficult access
Paracentesis guidance if needed
Disposition
Level of care criteria
Discharge suitability
Mild symptoms controlled with oral regimen
No history of DT or withdrawal seizures
No significant comorbidity
Reliable support
Safe environment
Inpatient ward indications
Moderate symptoms requiring repeated dosing
Unreliable outpatient follow up
Significant electrolyte derangements
Pregnancy
Frailty or significant comorbidity
ICU indications
Delirium tremens
Recurrent seizures
Severe autonomic instability
Need for phenobarbital loading with close monitoring
Need for dexmedetomidine or propofol infusion
Transfer criteria
No ICU capability locally
Refractory withdrawal despite escalating therapy
Need for mechanical ventilation
Consults and pathways
Consultation triggers
Critical care for DT or refractory withdrawal
Toxicology for phenobarbital strategy and mixed intoxication
Psychiatry for primary psychosis or safety concerns
Addiction medicine for initiation of alcohol use disorder treatment
Post-acute planning
Withdrawal stabilized to transition to AUD treatment
Community detox linkage when appropriate
Treatment
Core supportive care
Support bundle
Thiamine
Thiamine IV 500 mg every 8 hours for 2 to 3 days for suspected Wernicke encephalopathy
Then thiamine IV or PO 250 mg daily for 3 to 5 days
Then thiamine PO 100 mg daily
Dextrose
Dextrose IV for hypoglycemia after thiamine when feasible
Fluids
Isotonic crystalloid for hypovolemia
Avoid excessive free water with hyponatremia risk
Electrolytes
Magnesium sulfate IV replacement when low or suspected
Typical severe depletion strategy
Magnesium sulfate IV 2 g to 4 g
Repeat based on level and symptoms
Potassium replacement
Replace after magnesium strategy if both low
Phosphate replacement
Moderate to severe hypophosphatemia protocol per local standard
Vitamins
Folic acid PO 1 mg daily
Multivitamin supplementation
Benzodiazepines
First line therapy
Diazepam
Symptom triggered bolus
Diazepam PO or IV 10 mg to 20 mg
Repeat every 5 to 15 minutes for severe agitation until controlled
Longer acting agent for smoother course
Front loading approach
Diazepam IV 10 mg every 5 to 10 minutes
Typical total 40 mg to 100 mg
Stop when calm but arousable
Lorazepam
Preferred in severe liver disease or older adults
Lorazepam IV 2 mg to 4 mg
Repeat every 10 to 20 minutes as needed
Continuous dosing pathway
Lorazepam IV 1 mg to 2 mg every 1 to 2 hours
Escalate to infusion only in ICU setting
Chlordiazepoxide
Oral option for mild to moderate withdrawal
Chlordiazepoxide PO 25 mg to 50 mg
Repeat every 4 to 6 hours
Safety considerations
Respiratory depression risk
Co-ingested opioids
OSA
COPD
Paradoxical agitation consideration
Escalate to phenobarbital strategy if suspected
Phenobarbital
Indications and approach
Benzodiazepine resistant withdrawal
Persistent agitation despite high dose benzodiazepines
Autonomic instability despite therapy
Loading strategy
Phenobarbital IV 10 mg/kg to 15 mg/kg total load
Divide into 130 mg to 260 mg IV doses
Repeat every 15 to 30 minutes until target achieved
Maintenance strategy
Phenobarbital PO 60 mg to 130 mg every 8 to 12 hours
Taper based on clinical course
Monitoring and contraindications
Continuous monitoring for respiratory depression
Avoid in severe respiratory failure without ICU support
Additive sedation with benzodiazepines
Adjuncts and rescue therapies
Alpha-2 agonist adjunct
Dexmedetomidine
ICU adjunct for autonomic hyperactivity
Does not prevent seizures
Use only with adequate GABAergic therapy onboard
Anesthetic sedation
Propofol
Refractory DT requiring intubation
Provides GABAergic effect and seizure protection
Antipsychotics
Haloperidol
Severe hallucinations or agitation adjunct
Does not treat withdrawal pathophysiology
Seizure threshold lowering consideration
QT prolongation monitoring
Symptom adjuncts
Antiemetic
Ondansetron PO or IV 4 mg to 8 mg as needed
Analgesia
Avoid routine opioids
Consider acetaminophen dose adjustment in liver disease
Seizure management
Single withdrawal seizure
Benzodiazepine optimization
No routine long term antiepileptic initiation for isolated withdrawal seizure
Status epilepticus
Standard status pathway
Benzodiazepine first
Escalation per ICU protocol
Alcohol use disorder treatment initiation
In hospital linkage
Brief intervention
Referral to treatment
Pharmacotherapy planning after stabilization
Naltrexone consideration
Avoid in acute hepatitis or opioid use
Acamprosate consideration
Renal dosing considerations
Disulfiram consideration
Only with strong supervision and motivation
Special Populations
Pregnancy
Pregnancy considerations
Maternal and fetal risks
Withdrawal linked to fetal distress risk
Low threshold for admission
Medication considerations
Benzodiazepines acceptable when benefits outweigh risks
Avoid undertreatment of severe withdrawal
Obstetric involvement
Fetal monitoring when viable gestational age
Delivery planning if unstable
Geriatric
Older adult considerations
Presentation differences
Lower dose requirements
Higher delirium risk from comorbidity
Medication strategy
Prefer lorazepam over diazepam with liver disease and frailty
Slower titration
Complication vigilance
Falls
Aspiration
Arrhythmia
Pediatrics
Pediatric considerations
Epidemiology
Withdrawal uncommon but possible with heavy sustained use
Dosing framework
Weight based benzodiazepines per pediatric protocol
ICU threshold lower for severe agitation
Safeguarding
Screening for neglect and abuse
Involvement of guardians and social work
Background
Epidemiology
Alcohol withdrawal overview
Occurs after abrupt reduction or cessation in dependent individuals
DT is the most severe withdrawal form
DT historically associated with substantial mortality without treatment
Risk factors for severe withdrawal
Prior delirium tremens
Prior withdrawal seizures
Heavy daily intake
Older age
Significant medical comorbidity
Electrolyte abnormalities
Pathophysiology
Neuroadaptation model
Chronic alcohol effect
GABA-A enhancement
NMDA inhibition
Compensatory changes
GABA downregulation
NMDA upregulation
Withdrawal state
CNS hyperexcitability
Autonomic hyperactivity
Seizure mechanism
Lowered seizure threshold from glutamatergic excess
Delirium tremens mechanism
Widespread neurotransmitter imbalance
Sympathetic surge
Therapeutic Considerations
Treatment principles
GABAergic therapy as disease modifying treatment
Benzodiazepines first line
Phenobarbital as alternative or adjunct
Symptom triggered dosing evidence base
Reduces total benzodiazepine exposure in appropriate patients
Requires reliable scoring and staffing
Thiamine as neuroprotection
Prevents and treats Wernicke encephalopathy risk
Adjunct limitations
Alpha-2 agonists reduce autonomic symptoms but not seizure risk
Antipsychotics treat agitation but not underlying withdrawal
Guideline evidence framing
Class I recommendation for benzodiazepines as first line in severe withdrawal based on consensus and broad evidence
Phenobarbital supported as effective option in selected patients in multiple protocols and studies
ACEP Level C style evidence statements often apply to adjunct selection and disposition decisions when RCT data limited
Patient Discharge Instructions
copy discharge instructions
Discharge plan
No alcohol use while on sedating medications
No driving or operating machinery for 24 hours after last sedating dose
Hydration and nutrition
Regular fluids
Small frequent meals
Vitamins
Thiamine as prescribed
Folic acid as prescribed
Follow up
Primary care within 2 to 7 days
Addiction treatment referral within 1 week
Return to ED now
Confusion
Hallucinations
Seizure
Chest pain
Shortness of breath
Persistent vomiting
Black stools
Fever
Severe tremor or agitation not controlled
Harm reduction
Avoid abrupt stopping without medical plan if heavy daily use resumes
Do not mix alcohol with benzodiazepines or opioids
Crisis support access if feeling unsafe
References
Guidelines and high yield sources
Source set
American Society of Addiction Medicine clinical guideline for alcohol withdrawal management
Severity stratification
Benzodiazepine first line recommendations
Level of care guidance
NICE guideline on alcohol use disorders
Acute withdrawal and delirium management pathways
Thiamine prophylaxis recommendations
VA and DoD clinical practice guidance for substance use disorders
Withdrawal and AUD pharmacotherapy considerations
Evidence and reviews
Benzodiazepines efficacy for preventing seizures and DT supported by broad evidence base
Phenobarbital protocols supported by observational studies and growing comparative literature
Dexmedetomidine and propofol roles primarily ICU adjunct or rescue
Internal project specification citation
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.